GPR3 in neuro-metabolic-immune-reproductive nexus - a potential therapeutic target for Multi-System diseases.

Ann MedJan 23, 2026 (epub)

Bi-Dan Feng, Ji-Yao Qin, Qian-Qiong Qin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined GPR3, an orphan G-protein-coupled receptor, across neurological, metabolic, immune, and reproductive systems, drawing on a literature search of PubMed and Web of Science. The review describes GPR3 as having context-dependent effects: it promotes amyloid-β formation in Alzheimer’s disease while providing neuroprotection in Parkinson’s disease models. It also discusses possible roles in mood-related behaviours, oocyte meiotic arrest, adipose thermogenesis, and immune responses. The authors identify GPR3 as a potential therapeutic target but emphasize that its opposing effects in different disease contexts and challenges in translation require further research.

Key findings

  • GPR3 was reported to promote amyloid-β formation in Alzheimer’s disease, but to provide neuroprotection in Parkinson’s disease models.
  • The review links GPR3 to neuronal survival, synaptic plasticity, and microglial activity through cAMP/PKA, PI3K/Akt, and β-arrestin pathways.
  • GPR3 may maintain oocyte meiotic arrest and activate thermogenic genes in adipose tissue.
  • The review discusses OA and DPI as activators and AF64394 and CBD as antagonists in disease models.

Why it matters

The review brings together evidence that GPR3 may influence several physiological systems, while its effects can differ by disease context. This breadth makes it a candidate for further investigation in multisystem disorders, but also cautions against assuming that modulating the receptor would have uniformly beneficial effects across conditions.

What to keep in mind

As a systematic review, the paper synthesizes existing evidence rather than testing a clinical intervention. The abstract notes that translation challenges and GPR3’s dual roles in some pathologies remain unresolved.

Source

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.